The ARHGAP30 Activators consist of chemical compounds selected for their ability to enhance the functional activity of ARHGAP30, a regulator of the Rho family of GTPases which influences actin cytoskeleton dynamics and cell motility. Compounds like Y-27632, a ROCK inhibitor, and Rhosin, which inhibits RhoA activation, are crucial as they modulate Rho signaling pathways and could amplify ARHGAP30's regulatory effects on cytoskeletal organization. The presence of NSC23766 and EHT 1864, inhibitors of Rac1 and Rac respectively, alongside ML141 and CASIN, inhibitors of Cdc42, highlights the focus on modulating GTPase signaling to increase the functional demand and thus the activity of ARHGAP30 in compensatory regulation.
Additionally, compounds targeting cytoskeletal components and dynamics, such as CK-666, an Arp2/3 complex inhibitor, SMIFH2, a formin inhibitor, and Blebbistatin, a myosin II inhibitor, are included under the hypothesis that altering actin polymerization and cell contractility might indirectly enhance ARHGAP30's role in actin cytoskeleton remodeling. Latrunculin B and Jasplakinolide, which disrupt and stabilize actin filaments respectively, offer insights into how changes in actin dynamics can influence the activity of ARHGAP30. These compounds collectively represent a strategic approach to investigating and enhancing the activity of ARHGAP30, demonstrating the complex interplay between GTPase signaling, actin cytoskeleton organization, and cellular movement, and highlighting the ability for targeted intervention in these pathways for research applications.
SEE ALSO...
Items 471 to 11 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|